Search

Search Results

• CLINICAL CARE PATHWAY AND MANAGEMENT OF MAJOR BLEEDING ASSOCIATED WITH NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS: A MODIFIED DELPHI CONSENSUS FROM SAUDI ARABIA AND UAE

  Abdulrahman Al Raizah, Fakhr Alayoubi, Galal Hassan Abdelnaby, Hazzaa Alzahrani, Majid Farraj Bakheet, Mohammed A Alskaini, Rasha Buhumaid, Sameer Al Awadhi, Sara Nooruddin Kazim, Thiagarajan Jaiganesh, Zohair Al Asiri

  e2024038

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.038

  2642

  PDF: 1250

  HTML: 126

• CLASSICAL HODGKIN LYMPHOMA TODAY

  Francesco D'Alò, Gabriele Schiaffini, Daniele Mazzoni, Eleonora Alma, Flaminia Bellisario, Marcello Viscovo, Elena Maiolo, Silvia Bellesi, Stefan Hohaus

  2026-06-30

  https://doi.org/10.4084/MJHID.2026.055

  837

  PDF: 496

  HTML: 191

• Morphologic leukemia-free state after venetoclax-based therapy in acute myeloid leukemia is associated with high relapse despite preserved short-term survival

  Kenta Motegi

  e2026048

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.048

  390

  PDF: 380

  HTML: 248

• First-Line Flumatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A 3-Month Landmark-Evaluable Real-World Experience

  Dangui Chen

  e2026066

  2026-09-01

  https://doi.org/10.4084/MJHID.2026.066

  51

  PDF: 31

  Html: 5

• EFFICACY AND SAFETY OF THALIDOMIDE IN PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA: A SYSTEMATIC REVIEW, META-ANALYSIS AND GRADE EVALUATION

  Jialian Li, Ping Ji, Qinyue Zhong, Lin Dong, Hai Yi, Baiyu Chen, Xu Zhang, Tingting Duan

  e2026033

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.033

  342

  PDF: 362

  Suppl. Files: 57

  HTML: 91

• Ruxolitinib-Treated Myeloproliferative Neoplasms: Real-World Infectious Outcomes and Preventive Practices from a Single Center

  Muruvvet Seda Aydin, Gulten Korkmaz, Merve Pamukcuoglu, Hatice Rahmet Guner, Funda Ceran, Simten Dagdas, Gulsum Ozet

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.044

  287

  PDF: 376

  HTML: 74

• ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OF THE ELDERLY: REVIEW OF THE LITERATURE AND PERSPECTIVES. Hematopoietic stem cell transplatation in the elderly fo Acute Myeloid Leukemia

  Gabriele Magliano, Andrea Bacigalupo

  e2020081

  2020-10-27

  https://doi.org/10.4084/mjhid.2020.081

  1752

  PDF: 539

  HTML: 350

• THE IMPACT OF PRE-ANALYTICAL FACTORS ON BLOOD GLUCOSE MEASUREMENTS AND  and recommendations THE IMPACT OF PRE-ANALYTICAL FACTORS ON BLOOD GLUCOSE MEASUREMENTS AND RECOMMENDATIONS  FOR CLINICAL PRACTICE: AN ICET-A MULTICENTER SURVEY IN TRANSFUSION-DEPENDENT Β THALASSEMIA (Β-TDT) PATIENTS

  Vincenzo De Sanctis, Christos Kattamis, Duran Canatan, Defne Ay Tuncel, Sule Unal , Dulani Kottahachchi, Mohamed A Yassin, Ashraf T Soliman, Saif Al Yaarubi , Yasser Wali, Mehran Karimi, Forough Saki, Mohammad Faranoush, Polyxeni Delaporta, Antonis Kattamis, Iskra Modeva, Ploutarchos Tzoulis, Shahina Daar, Irene Savvidou

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.035

  412

  PDF: 420

  HTML: 50

• ACUTE MYELOİD LEUKEMİA, MYELODYSPLASİA-RELATED: BEYOND CLASSİFİCATİON—TOWARD PRECİSİON DECİSİON-MAKİNG

  G Leone, U Testa, E Attardi, MT Voso

  e2026075

  2026-09-01

  https://doi.org/10.4084/MJHID.2026.075

  87

  PDF: 68

  Html: 15

• OUTCOME OF FRONTLINE TREATMENT WITH “GENERIC” IMATINIB IN ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN ALGERIAN POPULATION: A MULTICENTER STUDY

  Mohamed Amine BEKADJA

  e2017062

  2017-10-25

  https://doi.org/10.4084/mjhid.2017.062

  2962

  PDF: 753

  HTML: 919

• The MINI-POLATUZUMAB VEDOTINE PLUS CHP (POLA-R-CHP) VS. MINI-R-CHOP IN PATIENTS OVER 80 YEARS OF AGE WITH DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE, PROPENSITY SCORE-MATCHED ANALYSIS STRATIFIED BY SIMPLIFIED FRAILTY SCORE PolaRCHP vs. RCHOP for older patients

  Shuku Sato

  e2025070

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.070

  1464

  PDF: 487

  HTML: 155

• THE PERFORMANCE OF HOMA 2 COMPARED TO DYNAMIC MARKERS OF INSULIN SECRETION AND SENSITIVITY/RESISTANCE FOR PREDICTING DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β-THALASSEMIA: THE EXPERIENCE OF A SINGLE CENTRE HOMA 2 and DYNAMIC MARKERS OF INSULIN SECRETION FOR PREDICTING DYSGLYCEMIA  in TDT

  Vincenzo De Sanctis, Shahina Daar, Ploutarchos Tzoulis, Ashraf Soliman, Ihab Elhakim , Mohammad Faranoush, Christos Kattamis

  e2026055

  2026-06-30

  https://doi.org/10.4084/MJHID.2026.056

  196

  PDF: 189

  HTML: 49

• REAL WORLD DATA ON CHARACTERISTICS AND MANAGEMENT OF COMMUNITY PATIENTS RECEIVING ANTICOAGULATION THERAPY WHO PRESENTED WITH ACUTE BLEEDING TO THE EMERGENCY DEPARTMENT AT A REGIONAL AUSTRALIAN HOSPITAL: A PROSPECTIVE OBSERVATIONAL STUDY. Anticoagulation and bleeding ?

  Fayez Hanna, Annemarie Hyppa, Ajay Prakash, Usira Vithanarachchi, Hizb U Dawar, Zar Sanga, George Olabode, Hamish Crisp, Professor Alhossain A. Khalafallah

  e2021017

  2021-02-26

  https://doi.org/10.4084/mjhid.2021.017

  1740

  PDF: 589

  HTML: 424

• TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS

  Luca Maurillo, Francesco Buccisano, Maria Ilaria Del Principe, Chiara Sarlo, Luigi Di Caprio, Concetta Ditto, Federica Giannotti, Daniela Nasso, Eleonora Ceresoli, Massimiliano Postorino, Marco Refrigeri, Sergio Amadori, Adriano Venditti

  e2013032

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.032

  2930

  PDF: 1052

  HTML: 5641

• RISK FACTORS ASSOCIATED WITH MORTALITY IN NOSOCOMIAL STENOTROPHOMONAS MALTOPHILIA PNEUMONIA: A SINGLE-CENTER RETROSPECTIVE STUDY-

  Yeşim Yıldız, Özge Özgen Top, Pınar Aysert Yıldız, Dr. Tekin Tas, Sedanur Eser, Hamid Habibi, Murat Dizbay

  e2026018

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.018

  646

  PDF: 627

  HTML: 103

• PLASMA CELL LEUKEMIA UPDATE ON IMMUNOPHENOTYPE, MOLECULAR CHARACTERISTICS, AND THERAPY. The second part of plasma cell neoplasms with spreading in the blood and tissues Plasma Cell Leukemia

  Giuseppe G.M. Leone, Ugo Testa

  e2025080

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.080

  1693

  PDF: 411

  Html: 234

• IMPACT OF QUALITATIVE AND QUANTITATIVE IMMUNOPARESIS ON EARLY INFECTION RISK IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA Immunoparesis and early infection risk in myeloma

  Hongfeng Wang, Jianbin Chen

  e2026062

  2026-06-30

  https://doi.org/10.4084/MJHID.2026.062

  200

  PDF: 678

  HTML: 64

• EVOLVİNG PARADİGMS İN THE MANAGEMENT OF PRİMARY IMMUNE THROMBOCYTOPENİA İN ADULTS: FROM CORTİCOSTEROİDS TO TARGETED BİOLOGİC THERAPİES

  Massimo Martino, Laura Giordano, Maria Bruna Greve, Violetta Marafioti, Caterina Alati

  e2026067

  2026-09-01

  https://doi.org/10.4084/MJHID.2026.067

  74

  PDF: 75

  Html: 5

• THE CHALLENGE OF AML IN OLDER PATIENTS

  Alan K Burnett

  e2013038

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.038

  2409

  PDF: 1025

  HTML: 2226

• PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma

  Ugo Testa; Giuseppe G.M. Leone

  e2025005

  2024-12-31

  https://doi.org/10.4084/MJHID.2025.005

  2562

  HTML: 305

  PDF: 942

• COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.

  Monia Marchetti , Robert Peter Gale, Giovanni Barosi

  Page e2021034

  2021-04-29

  https://doi.org/10.4084/MJHID.2021.034

  1562

  PDF: 577

  HTML: 254

• Psychiatric Symptoms after H1N1 Influenza Treated with Baloxavir Marboxil in Two Patients with Hematologic Malignancies

  Zhan Su, Xiaojia Bu, Yao Li

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.031

  594

  PDF: 447

  HTML: 248

• Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA

  Michele Puppi, Ilaria Sacchetti, Katia Mancuso, Paola Tacchetti, Lucia Pantani, ilaria Rizzello, Miriam Iezza, Marco Talarico, Enrica Manzato, Simone Masci, Roberta Restuccia, Simona Barbato, Silvia Armuzzi, Barbara Taurisano, Ilaria Vigliotta, Elena Zamagni

  e2025045

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.045

  1795

  PDF: 1323

  HTML: 629

• SOCIAL AND FINANCIAL BARRIERS TO OPTIMUM TKI TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA- A KNOWLEDGE-ATTITUDES-PRACTICES STUDY FROM INDIA

  Naveen Gupta, Manoranjan Mahapatra, Tulika Seth, Seema Tyagi, Sudha Sazawal, Renu Saxena

  e2021004

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.004

  2028

  PDF: 606

  HTML: 289

• CD56⁺/CD38⁺ Neutrophils: Rapid and Specific Flow Cytometric Signature for Chronic Myeloid Leukemia

  Alessandro Laganà, Matteo Breccia, Loredana Elia, Emilia Scalzulli, Maria Laura Bisegna, Claudia Ielo, Sonia Buffolino, Attilio Di Lascio, Concetta Anna Germano, Stefania Intoppa, Maria Laura Milani, Maurizio Martelli, Massimo Breccia, Maria Stefania De Propris

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.049

  297

  PDF: 319

  Suppl. Files: 64

  HTML: 63

• Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.

  Stefano Molica, Paolo Sportoletti, Nicola Di Renzo, Pellegrino Musto, Fabrizio Pane, Francesco Di Raimondo

  e2021042

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.042

  1510

  PDF: 535

  HTML: 230

• Validation of a New Scoring System for Treatment Failure in CML Patients on Tyrosine Kinase Inhibitors in a real world setting

  Andrea Mattozzi, Eugenio Galli, Francesco Autore, Ilaria Pansini, Patrizia Chiusolo, Simona Sica, Federica Sorà

  e2026013

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.013

  656

  PDF: 561

  Html: 92